Columbia Trust Co 01012016 Buys 456 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Columbia Trust Co 01012016 grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,153 shares of the medical research company’s stock after buying an additional 456 shares during the quarter. Thermo Fisher Scientific makes up 1.0% of Columbia Trust Co 01012016’s holdings, making the stock its 25th biggest holding. Columbia Trust Co 01012016’s holdings in Thermo Fisher Scientific were worth $1,802,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of TMO. Price T Rowe Associates Inc. MD grew its stake in shares of Thermo Fisher Scientific by 19.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 13,316,751 shares of the medical research company’s stock worth $6,717,901,000 after buying an additional 2,133,690 shares during the last quarter. Amundi bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $893,779,000. Putnam Investments LLC grew its stake in shares of Thermo Fisher Scientific by 152.7% during the second quarter. Putnam Investments LLC now owns 1,109,316 shares of the medical research company’s stock worth $559,617,000 after buying an additional 670,372 shares during the last quarter. Flossbach Von Storch AG grew its stake in shares of Thermo Fisher Scientific by 130.6% in the second quarter. Flossbach Von Storch AG now owns 796,673 shares of the medical research company’s stock worth $401,898,000 after purchasing an additional 451,134 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Thermo Fisher Scientific by 10.6% in the second quarter. Bank of New York Mellon Corp now owns 3,993,588 shares of the medical research company’s stock worth $2,014,647,000 after purchasing an additional 381,863 shares during the last quarter. 85.47% of the stock is currently owned by hedge funds and other institutional investors.

In other Thermo Fisher Scientific news, COO Mark Stevenson sold 26,925 shares of the stock in a transaction dated Monday, November 1st. The shares were sold at an average price of $632.69, for a total value of $17,035,178.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 22,550 shares of the stock in a transaction dated Tuesday, November 2nd. The shares were sold at an average price of $638.10, for a total transaction of $14,389,155.00. The disclosure for this sale can be found here. Corporate insiders own 0.44% of the company’s stock.

Several analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, September 20th. They issued a “hold” rating and a $540.00 price objective on the stock. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $635.00 to $657.00 and gave the stock an “outperform” rating in a research note on Thursday, October 28th. The Goldman Sachs Group raised shares of Thermo Fisher Scientific from a “buy” rating to a “conviction-buy” rating in a research note on Thursday, September 23rd. Morgan Stanley began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, October 28th. They set an “overweight” rating on the stock. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific from $595.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, September 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $613.89.

Shares of NYSE TMO opened at $633.00 on Thursday. The firm’s 50-day moving average price is $606.29 and its 200-day moving average price is $544.24. Thermo Fisher Scientific Inc. has a 1-year low of $433.52 and a 1-year high of $651.57. The firm has a market capitalization of $249.43 billion, a P/E ratio of 29.41, a P/E/G ratio of 1.93 and a beta of 0.72. The company has a current ratio of 3.19, a quick ratio of 2.56 and a debt-to-equity ratio of 0.56.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 27th. The medical research company reported $5.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.67 by $1.09. Thermo Fisher Scientific had a net margin of 21.93% and a return on equity of 28.14%. The company had revenue of $9.33 billion for the quarter, compared to analyst estimates of $8.41 billion. During the same quarter in the prior year, the business posted $5.63 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.4 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Thursday, September 23rd that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 1.3% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 14th. Investors of record on Wednesday, December 15th will be issued a $0.26 dividend. The ex-dividend date of this dividend is Tuesday, December 14th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.16%. Thermo Fisher Scientific’s dividend payout ratio is presently 4.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Featured Story: retirement calculator

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.